QUANTM Irradiation System™ Earns CE Mark Approval
ARTMS Products today announced it received CE marking approval for its first-in-class, advanced technology QUANTM Irradiation System™ for producing high-value radioisotopes, such as Tc-99m and Ga-68, on medical cyclotrons. Cyclotron facilities are constantly facing higher isotope costs and poor supply availability. Now, with CE marking, ARTMS’ QUANTM Irradiation System™ will help ease these issues.
"CE marking is an important milestone for ARTMS," remarked Dr. Kaley Wilson, CEO of ARTMS Products. "There is a huge opportunity in providing a cost effective and secured supply of radioisotopes to hospitals and research institutions. ARTMS provides a more economical, environmentally safe and secured supply of important radioisotopes than reactor-based sources. Now, with CE marking approval, ARTMS can be readily integrated in a standardized fashion into existing and emerging facilities which ultimately leads to improved patient access and care across Europe."
Giving Cyclotron Facilities More Control Over the Supply of Medical Isotopes
Unlike traditional reactor and generator production methods, which are growing increasingly more expensive and cannot consistently supply user requirements, the ARTMS QUANTM Irradiation System™ combines both local production control and a cost-effective, easy-to-use solid target system for production of radioisotopes on medical cyclotrons. Medical radioisotopes are used in the field of nuclear medicine on a daily basis for both medical diagnostic imaging and therapy, particularly in the fields of oncology, cardiology and neurology.
The ARTMS QUANTM Irradiation System™ is currently available for most OEM cyclotron systems and has been installed and is operating in a number of countries.
About ARTMS Products
Based in Vancouver, British Columbia, ARTMS Products Inc. is a leader in the development of novel technologies and products which enable the production of the world’s most-used diagnostic imaging isotope, technetium-99m (Tc-99m), using local, hospital-based medical cyclotrons. ARTMS holds the exclusive global commercialization rights to award-winning and proprietary Canadian inventions which address these challenges, and which offer the prospect of revolutionizing the nuclear medicine industry.
ARTMS Products Inc.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
CA-AXONICS10.12.2018 17:05 | Pressemeddelelse
Axonics® Announces Publication of NICE Briefing
GLOBAL-BLOCKCHAIN-ASSOC10.12.2018 16:02 | Pressemeddelelse
The Largest Blockchain Conference in Asia to Be Held 30–31 January in Yokohama, Japan
GA-GLOBAL-PAYMENTS10.12.2018 14:32 | Pressemeddelelse
Global Payments’ TouchNet Business Named “Partner of the Year” by Ellucian
FL-CTS-ENGINES10.12.2018 14:02 | Pressemeddelelse
CTS Engines Hires Tom Bode as Senior Vice President, Operations
TRACXPOINT10.12.2018 12:02 | Pressemeddelelse
Tracxpoint Signed a Major Agreement to Deploy its Artificial Intelligence Cart (AiC®) Platform at CONAD, One of the Largest and Most Sophisticated Supermarket Chains in Italy with 3,000 Locations in Lieu of Amazon Go after Intensive Study
JETEX10.12.2018 10:54 | Pressemeddelelse
Jetex Now the Exclusive Dealer in the Middle East for Hi-Tech New HondaJet
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum